½ÃÀ庸°í¼­
»óǰÄÚµå
1267451

¼¼°èÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå - Á¦Ç°º°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµ ¹× ¿¹Ãø(2023-2032³â)

Remote Patient Monitoring Devices Market - By Product, By Application, By End-use & Forecast, 2023 - 2032

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Global Market Insights Inc. | ÆäÀÌÁö Á¤º¸: ¿µ¹® 290 Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ÀåºñÀÇ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2032³â±îÁö Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

À¯·´°ú ºÏ¹Ì µî ¼±Áø±¹ÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ Àåºñ µµÀÔÀº ³ë·É Àα¸ÀÇ Áõ°¡·Î ÀÎÇØ ÇâÈÄ 10³â°£ ½ÃÀå Àü¸ÁÀ» °­È­ÇÒ °ÍÀ̸ç, Eurostat¿¡ µû¸£¸é 2022³â¿¡´Â EU Àα¸ÀÇ ¾à 5ºÐÀÇ 1¿¡ ÇØ´çÇÏ´Â 21.1% ÀÌ»óÀÌ 65¼¼ ÀÌ»óÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÀÌ »ç¾÷ ºÐ¾ßÀÇ ¸¹Àº ±â¾÷µéÀº ¾÷°è ÁöÀ§¸¦ ³ôÀ̱â À§ÇØ Çù¾÷ Àü·«¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 10¿ù ¹Ì±¹ÀÇ ´Ù±¹Àû ÀÇ·á ±â¼ú ±â¾÷ÀÎ GEÇコÄɾî´Â ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ¼Ö·ç¼ÇÀÇ ¼±µÎ ¾÷üÀÎ AMCÇコ(AMC Health)¿Í °è¾àÀ» ü°áÇß½À´Ï´Ù. º´¿øÀÇ ±Þ¼º±â ȯÀÚ ¸ð´ÏÅ͸µ ¼Ö·ç¼Ç°ú AMC HealthÀÇ FDA Class II 510(k) ½ÂÀÎ Ç÷§ÆûÀ» ÅëÇØ AMC HealthÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ Àü¹®¼ºÀ» ÅëÇÕÇÏ¿© ºñ±Þ¼º±â ÀÇ·áÀÇ ¿¬¼Ó¼ºÀ» È®ÀåÇÏ´Â µ¥ µµ¿òÀÌ µÉ °ÍÀÔ´Ï´Ù.

Àüü ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀåÀº Á¦Ç°, ÀÀ¿ë ÇÁ·Î±×·¥, ÃÖÁ¾ ¿ëµµ ¹× Áö¿ª¿¡ µû¶ó ¼¼ºÐÈ­µË´Ï´Ù.

½Å°æ°è ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ Àåºñ »ê¾÷Àº 2032³â±îÁö »ó´çÇÑ ÀÌÀÍÀ» ¾òÀ» °ÍÀ¸·Î º¸ÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÀåºñÀÇ ºñ¿ë È¿À²¼ºÀ¸·Î ÀÎÇØ ¸¹Àº ȯÀÚµéÀÌ ÀÚ°¡ ¸ð´ÏÅ͸µÀ¸·Î ÀüȯÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Àå±âÀûÀ¸·Î ÀÌ ºÐ¾ßÀÇ ¼ºÀå¿¡ ±â¿©ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÆÄŲ½¼º´, Ä¡¸Å¿Í °°Àº ½Å°æ ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡Çϰí ÀÖ´Â °Íµµ Á¦Ç° ¼ö¿ä¸¦ ´õ¿í Áõ°¡½Ã۰í ÀÖÀ¸¸ç, WHO¿¡ µû¸£¸é Àü ¼¼°èÀûÀ¸·Î ¾à 5,500¸¸ ¸íÀÌ Ä¡¸Å¿Í ½Î¿ì°í ÀÖÀ¸¸ç ¸Å³â 1,000¸¸ ¸íÀÌ »õ·Ó°Ô Ä¡¸Å Áø´ÜÀ» ¹Þ°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

¿ëµµº°·Î´Â COPD, ¼¶À¯Áõ, õ½Ä µî È£Èí±â ÁúȯÀÇ ¹ß»ýÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ÀåºñÀÇ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖÀ¸¸ç, WHO¿¡ µû¸£¸é COPD´Â ¼¼°è 3À§ÀÇ »ç¸Á ¿øÀÎÀ¸·Î ¸Å³â Áß»êÃþ ÀÌ»ó ±¹°¡ÀÇ 70¼¼ ÀÌ»ó »ç¸ÁÀÚÀÇ 90%¸¦ Â÷ÁöÇÕ´Ï´Ù. ÁßÀú¼Òµæ ±¹°¡ 70¼¼ ¹Ì¸¸ Àα¸ÀÇ »ç¸Á¿øÀÎÀÇ ¾à 90%¸¦ ¸Å³â Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾»ç¿ëÀÚ °üÁ¡¿¡¼­ º¼ ¶§, 2032³â±îÁö Àå±â¿ä¾ç ºÐ¾ßÀÇ ½ÃÀåÁ¡À¯À²Àº ´«¿¡ ¶ç°Ô Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Àå±â¿ä¾ç½Ã¼³Àº ¼÷·ÃµÈ ÀÇ·á Àü¹®°¡°¡ »óÁÖÇϱ⠶§¹®¿¡ ¿ø°Ý ¸ð´ÏÅ͸µ ¼­ºñ½º¸¦ ÇÊ¿ä·Î Çϴ ȯÀÚµéÀÌ ¼±È£Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´õ ºü¸¥ ȸº¹À» ±â´ëÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ·¯ÇÑ ½Ã¼³¿¡ ´ëÇÑ È¯ÀÚµéÀÇ ÀÌ¿ëÀÌ Áõ°¡ÇÏ¿© ÀÌ ºÎ¹®ÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â »ê¾÷Àº 2023³âºÎÅÍ 2032³â±îÁö 11.5% ÀÌ»óÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¸¸¼º ÁúȯÀ» ¾Î°í ÀÖ´Â ³ëÀÎ Àα¸°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÀÌ Áö¿ª¿¡¼­´Â ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ Àåºñ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. Áß±¹ ±¹°¡À§»ýÀ§¿øÈ¸¿¡ µû¸£¸é, Áß±¹ÀÇ 60¼¼ ÀÌ»ó Àα¸´Â 2035³â±îÁö 2¾ï 8,000¸¸ ¸í¿¡¼­ 4¾ï ¸í ÀÌ»óÀ¸·Î Áõ°¡ÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. µû¶ó¼­ Áúº´ ºÎ´ãÀÇ Áõ°¡´Â ÀÌ Áö¿ªÀÇ ½ÃÀå È®´ë¿¡ À¯¸®ÇÏ°Ô ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ¾÷°è ÀλçÀÌÆ®

  • ¾÷°è »óȲ¿¡ ´ëÇØ
  • ¾÷°è¿¡ ´ëÇÑ ¿µÇâ¿äÀÎ
    • ÃËÁø¿äÀÎ
    • ¾÷°èÀÇ ÀáÀçÀû ¸®½ºÅ©£¦°úÁ¦
  • ¼ºÀ强 ºÐ¼®
    • Á¦Ç°º°
    • ¿ëµµº°
    • ÃÖÁ¾ ¿ëµµº°
  • COVID-19ÀÇ ¿µÇ⠺м®
  • ±â¼úÀûÀÎ Àü¸Á
  • ±ÔÁ¦ »óȲ¿¡ ´ëÇØ
    • ¹Ì±¹
    • À¯·´ÀÇ
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®

Á¦4Àå °æÀï ±¸µµ¿¡ ´ëÇØ

  • ¼­·Ð
    • Koninklijke Philips NV
    • Medtronic
    • Boston Scientific Corporation
  • °æÀï ´ë½Ãº¸µå, 2021³â
  • ÁÖ¿ä ½ÃÀå Ç÷¹ÀÌ¾î °æÀï ºÐ¼®
  • °æÀï Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º
  • Àü·«Àû Àü¸Á ¸ÅÆ®¸¯½º

Á¦5Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Á¦Ç°º°

  • ÁÖ¿ä Á¦Ç° µ¿Çâ
  • ½ÉÀå ¸ð´ÏÅ͸µ Àåºñ
  • Ç÷¾Ð ÃøÁ¤ Àåºñ
  • ´º·Î·ÎÁöÄ«¸£¸ð´ÏŸ Àåºñ
  • È£Èí±â ¸ð´ÏÅ͸µ Àåºñ
  • ¸ÖƼ ÆÄ¶ó¹ÌÅÍ ¸ð´ÏÅ͸µ Àåºñ
  • Ç÷´çÄ¡ ÃøÁ¤ Àåºñ Ç÷´çÄ¡ ÃøÁ¤ Àåºñ
  • žơ¤½Å»ý¾Æ ¸ð´ÏÅ͸µ Àåºñ
  • ¼ö¸é °¨½Ã Àåºñ
  • ±âŸ

Á¦6Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ¿ëµµº°

  • ÁÖ¿ä ¿ëµµ µ¿Çâ
  • ¼øÈ¯±â°è Áúȯ
  • ¾Ï(Cancer
  • ´ç´¢º´
  • ½Å°æ°è Áúȯ
  • °¨¿°Áõ
  • È£Èí±â Áúȯ
  • ±âŸ

Á¦7Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : ÃÖÁ¾ ¿ëµµº°

  • ÁÖ¿ä ÃÖÁ¾»ç¿ëÀÚ µ¿Çâ
  • ÀçÅð£È£ ÇöÀå
  • Àå±âÀûÀÎ Äɾî
  • ±âŸ

Á¦8Àå ¿ø°Ý ȯÀÚ ¸ð´ÏÅ͸µ ±â±â ½ÃÀå : Áö¿ªº°

  • ÁÖ¿ä Áö¿ª µ¿Çâ
  • ºÏ¹ÌÀÇ
    • ¹Ì±¹
    • ij³ª´Ù
  • À¯·´ÀÇ
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ÀÌÅ»¸®¾Æ
    • ·¯½Ã¾Æ
    • Æú¶õµå
    • ³×´ú¶õµå
  • ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ
    • Áß±¹
    • ÀϺ»
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ¾Æ¸£ÇîÆ¼³ª
    • ÄÝ·Òºñ¾Æ
    • Ä¥·¹
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« Áö¿ª
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • UAE
    • À̽º¶ó¿¤

Á¦9Àå ±â¾÷ °³¿ä

  • Koninklijke Philips N.V
  • Medtronic plc
  • OMRON Corporation
  • Boston Scientific Corporation
  • General Electric Company
  • F. Hoffmann-La Roche AG
  • Baxter International Inc.
  • Medtronic
  • DexCom, Inc.
  • Johnson & Johnson
  • VitalConnect
  • Abbott Laboratories
  • Cerner Corporation
  • Siemens Healthineers AG
LSH 23.05.11

Global Remote Patient Monitoring Devices Market size is expected to expand substantially through 2032. Given the growing geriatric population, the rising adoption of remote patient monitoring devices in developed regions such as Europe and North America will strengthen the market outlook over the next ten years. As per Eurostat, in 2022, over 21.1%, which makes up around one-fifth of the EU population, was 65 years and above.

Many companies in this business vertical are focusing on collaboration strategies to enhance their industry standing. For instance, in October 2022, GE Healthcare, an American multinational medical technology company, inked a deal with AMC Health, a leading provider of remote patient monitoring solutions. The integration of the company's acute patient monitoring solutions in hospitals and AMC Health's specialization in remote patient monitoring through an FDA Class II 510(k)-approved platform will help in the extension of the non-acute care continuum.

The overall remote patient monitoring devices market is segmented on the basis of product, application, end use, and region.

The remote patient monitoring devices industry from the neurological segment is poised to garner considerable gains through 2032. Owing to the cost-effectiveness of these devices, many patients are turning to self-monitoring activities which may contribute to segment growth in the long run. Moreover, the growing prevalence of neurological disorders such as Parkinson's disease, dementia, and others has further increased the product demand. According to WHO, around 55 million people globally are dealing with dementia, with an estimated 10 million new cases diagnosed every year.

With respect to application, the remote patient monitoring devices market revenue from the respiratory diseases segment is expected to reach over USD 6.5 billion in 2032. Rising occurrences of respiratory disorders such as COPD, fibrosis, asthma, and others have increased the need for remote patient monitoring devices. As per the WHO, COPD is the third-prominent cause of death globally, responsible for around 90% of mortalities in people under 70 years in low and middle-income economies every year.

In terms of end use, the overall market share from long-term care segment is anticipated to witness commendable growth through 2032. High availability of skilled healthcare professionals in these facilities has made them a preferred healthcare provider among patients that require remote monitoring services. They also help ensure faster and complete recovery, which increases patient footfalls in these facilities, thus, contributing to segment expansion.

Asia Pacific remote patient monitoring devices industry is expected to exhibit over 11.5% CAGR from 2023 to 2032. Rising elderly population suffering from chronic ailments has increased the need for remote patient monitoring devices in the region. As per China's National Health Commission, the population of people aged 60 and above in the country is estimated to increase from 280 million to over 400 million by 2035. The increasing disease burden will therefore favor the regional market expansion.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Methodology
  • 1.2 Market scope & definitions
  • 1.3 Base estimates and calculations
    • 1.3.1 North America
    • 1.3.2 Europe
    • 1.3.3 Asia Pacific
    • 1.3.4 Latin America
    • 1.3.5 MEA
  • 1.4 Forecast calculations
  • 1.5 Data validation
  • 1.6 COVID-19 impact analysis at global level
  • 1.7 Data sources
    • 1.7.1 Primary
    • 1.7.2 Secondary
      • 1.7.2.1 Paid sources
      • 1.7.2.2 Unpaid sources

Chapter 2 Executive Summary

  • 2.1 Remote patient monitoring devices industry 360 degree synopsis, 2018 - 2032
    • 2.1.1 Business trends (USD Million & Units)
    • 2.1.2 Product trends (USD Million & Units)
    • 2.1.3 Application trends (USD Million & Units)
    • 2.1.4 End-use trends (USD Million & Units)
    • 2.1.5 Regional trends (USD Million & Units)

Chapter 3 Remote Patient Monitoring Devices Industry Insights

  • 3.1 Industry landscape
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising incidence of chronic diseases across the globe
      • 3.2.1.2 Growing disposable income and healthcare expenditure in emerging countries
      • 3.2.1.3 Technological advancement in developed nations
      • 3.2.1.4 Growing adoption of remote patient monitoring devices
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High cost of devices
      • 3.2.2.2 Stringent regulatory framework
  • 3.3 Growth potential analysis
    • 3.3.1 By product
    • 3.3.2 By application
    • 3.3.3 By end-use
  • 3.4 COVID- 19 impact analysis
  • 3.5 Technological Landscape
  • 3.6 Regulatory landscape
    • 3.6.1 U.S.
    • 3.6.2 Europe
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape

  • 4.1 Introduction
    • 4.1.1 Koninklijke Philips NV
    • 4.1.2 Medtronic
    • 4.1.3 Boston Scientific Corporation
  • 4.2 Competitive dashboard, 2021
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategic outlook matrix

Chapter 5 Remote Patient Monitoring Devices Market, By Product

  • 5.1 Key product trends
  • 5.2 Cardiac monitoring devices
    • 5.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.2.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.3 Blood pressure monitoring devices
    • 5.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.3.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.4 Neurological monitoring devices
    • 5.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.4.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.5 Respiratory monitoring devices
    • 5.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.5.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.6 Multiparameter monitoring devices
    • 5.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.6.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.7 Blood glucose monitoring Devices
    • 5.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.7.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.8 Fetal and neonatal monitoring Devices
    • 5.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.8.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.9 Sleep monitoring devices
    • 5.9.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.9.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 5.10 Others
    • 5.10.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 5.10.2 Market estimates and forecast, 2018 - 2032 (Units)

Chapter 6 Remote Patient Monitoring Devices Market, By Application

  • 6.1 Key application trends
  • 6.2 Cardiovascular diseases
    • 6.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.2.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.3 Cancer
    • 6.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.3.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.4 Diabetes
    • 6.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.4.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.5 Neurological disorders
    • 6.5.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.5.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.6 Infectious diseases
    • 6.6.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.6.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.7 Respiratory diseases
    • 6.7.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.7.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 6.8 Others
    • 6.8.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 6.8.2 Market estimates and forecast, 2018 - 2032 (Units)

Chapter 7 Remote Patient Monitoring Devices Market, By End-use

  • 7.1 Key end-use trends
  • 7.2 Home-care settings
    • 7.2.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 7.2.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 7.3 Long-term care
    • 7.3.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 7.3.2 Market estimates and forecast, 2018 - 2032 (Units)
  • 7.4 Others
    • 7.4.1 Market estimates and forecast, 2018 - 2032 (USD Million)
    • 7.4.2 Market estimates and forecast, 2018 - 2032 (Units)

Chapter 8 Remote Patient Monitoring Devices Market, By Region

  • 8.1 Key regional trends
  • 8.2 North America
    • 8.2.1 U.S.
    • 8.2.2 Canada
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 France
    • 8.3.4 Spain
    • 8.3.5 Italy
    • 8.3.6 Russia
    • 8.3.7 Poland
    • 8.3.8 The Netherlands
  • 8.4 Asia Pacific
    • 8.4.1 China
    • 8.4.2 Japan
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 South Korea
    • 8.4.6 Thailand
  • 8.5 Latin America
    • 8.5.1 Brazil
    • 8.5.2 Mexico
    • 8.5.3 Argentina
    • 8.5.4 Columbia
    • 8.5.5 Chile
  • 8.6 Middle East & Africa
    • 8.6.1 South Africa
    • 8.6.2 Saudi Arabia
    • 8.6.3 UAE
    • 8.6.4 Israel

Chapter 9 Company Profiles

  • 9.1 Koninklijke Philips N.V
  • 9.2 Medtronic plc
  • 9.3 OMRON Corporation
  • 9.4 Boston Scientific Corporation
  • 9.5 General Electric Company
  • 9.6 F. Hoffmann-La Roche AG
  • 9.7 Baxter International Inc.
  • 9.8 Medtronic
  • 9.9 DexCom, Inc.
  • 9.10 Johnson & Johnson
  • 9.11 VitalConnect
  • 9.12 Abbott Laboratories
  • 9.13 Cerner Corporation
  • 9.14 Siemens Healthineers AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦